Apnimed Reports Q3 2026 Results and NDA for Oxnimbi Under FDA Review
Apnimed announced financial results with $351.8 million in cash and announced the NDA for Oxnimbi has a PDUFA goal date of February 28, 2027, marking a potential sales catalyst for the OSA treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed